Global brokerage Citi downgraded Lupin (NSE: LUPIN) to ‘Sell’ from ‘Buy’ and slashed its target price to Rs 2,050 from Rs 2,540, triggering a 1.84% intraday decline to Rs 2,144.70. According to reports citing a Citi note, the downward revision stems from mounting concerns over the erosion of Lupin’s high-margin US base business.
The Bottom Line
- The Downgrade: Citi cut Lupin’s target price by 19% to Rs 2,050, citing elevated execution risk in the US market.
- Margin Compression: Projections indicate EBITDA margins could contract from 30% down to 20% by FY29.
- Divergent Outlooks: While Citi warns of weakening base momentum, rival firm Bernstein maintains an ‘Outperform’ rating following a favorable patent ruling.
Unpacking Citi’s US Market Concerns
The core catalyst behind the broker’s bearish stance is the anticipated contraction of Lupin’s American operations. Citi projects that Lupin’s US sales will decline from roughly $1.3 billion in FY26 to $975 million by FY29. Analysts point to a lack of immediate pipeline substitutes to offset expected drops in key legacy products like gJynarque and gMyrbetriq. Here is the math: as these established revenue streams taper off, the company faces severe pressure on overall profitability.
Profit margins are expected to narrow significantly. Citi estimates EBITDA margins will slide from current levels near 30% down to 20% over the next few fiscal years. While products like Apixaban are projected to offer temporary earnings support in FY28, Citi views this tailwind as short-lived. Longer-term growth drivers—including Neulasta Onpro, Etanercept, and Spiriva Respimat—remain unfiled, severely limiting near-term visibility.
Divergent Analyst Views and Legal Wins
Not all institutional desks share Citi’s pessimistic outlook. Bernstein highlights a favorable August 24 judgment in the Kalydeco patent trial as a major positive catalyst.
The Delaware District Court ruled that Lupin’s generic formulation did not infringe four disputed Vertex patent claims. This legal victory removes the principal barrier to launching its first-to-file ivacaftor programme, which comes with 180 days of market exclusivity. Lupin already holds tentative US Food and Drug Administration (FDA) approval for the generic treatment used for cystic fibrosis. Bernstein estimates this single product could generate $20 million to $30 million in annual sales, offsetting some base business decay.
Technical Indicators and Market Performance
The stock’s recent price action mirrors the growing caution among institutional investors. Lupin shares declined approximately 10% over a trailing one-month window, bringing the company’s total market capitalisation to approximately Rs 98,497 crore. The stock previously touched a 52-week high of Rs 2,529.50.
On the charts, technical indicators show lingering weakness. Lupin’s 14-day Relative Strength Index (RSI) sits at 29.3, placing the equity firmly in oversold territory. While an RSI reading below 30 often signals potential for a short-term relief rally if buying interest returns, the broader trend remains decidedly bearish. The equity is currently trading below all eight key Simple Moving Averages (SMAs) tracked by market analysts, indicating broad-based downward momentum.
| Metric | Current Data / Estimate | Context |
|---|---|---|
| Market Capitalisation | Rs 98,497 crore | Reflects recent valuation adjustment |
| Citi Target Price | Rs 2,050 | Cut from Rs 2,540 following downgrade |
| Bernstein Target Price | Rs 2,707 | Maintains ‘Outperform’ rating |
| Projected US Sales (FY29) | $975 million | Down from $1.3 billion in FY26 |
| 14-Day RSI | 29.3 | Indicates oversold technical conditions |
Navigating Forward Earnings Risk
Reflecting its more conservative stance, Citi reduced its FY27 earnings-per-share (EPS) estimate by 14%. Investors monitoring the pharmaceutical sector will need to weigh near-term patent litigation victories against structural margin compression in legacy portfolios before committing fresh capital.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
